← Enlivex Therapeutics Ltd. (ENLV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Enlivex Therapeutics Ltd. (ENLV)
Pharmaceutical Preparations · market cap $11M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-02 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Enlivex Therapeutics Ltd. (ENLV) is a small-cap Israeli pharmaceutical company with 34 employees and a ~$150M market cap, developing Allocetra, a cell-therapy platform in Phase 2 for knee osteoarthritis and, under the OTS formulation, for sepsis. The next major scheduled catalyst is an estimated February 2026 Phase 2 data readout for the osteoarthritis program, rated 7/10 importance by CatalystAlert.
The catalyst path
- 2026-10-02 (est.)Earningsimp 5/10
- 2027-02-15 (est.)Phase 2 · Allocetraimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Allocetra | Phase 2 | Osteoarthritis, Knee |
| Allocetra-OTS | Phase 2 | Sepsis |
Price & technical context
3-month
-94.7%
6-month
-97.1%
12-month
-97.3%
52-wk range
$0.42–$18.15
vs 50-day MA
-72.2%
vs 200-day MA
-95.8%
Realized vol
105.6%
Max drawdown
-98.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ENLV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.